Full-Time
Associate Director
Business Development
Confirmed live in the last 24 hours
Element Biosciences
201-500 employees
Biotechnology firm specializing in DNA sequencing
Compensation Overview
$156k - $200k/yr
Senior, Expert
San Diego, CA, USA
This is an on-site role based in San Diego.
- A Bachelor’s degree in Business, Life Sciences, or a related field. Advanced degrees are a plus
- 7+ years of related experience in corporate/business development role with responsibilities of developing strategies, business cases, negotiating and executing contracts
- Ability to thrive in a collaborative work environment, interacting effectively with peers, functional managers, and senior leadership
- Highly effective organizational and planning abilities
- Identify, develop business cases including financial modeling, negotiate, and manage partnerships with biotechnology, pharmaceutical, academic, and healthcare organizations to accelerate growth, research collaborations, and product development
- Conduct thorough market research and competitive analysis to inform business development strategies and identify emerging trends
- Oversee and manage a pipeline of potential partnerships from early-stage discussions through agreement execution and integration
- Drive new revenue streams through the identification and execution of licensing deals, joint ventures, and other strategic collaborations
- Work closely with internal teams such as R&D, legal, regulatory, and marketing & sales to ensure alignment on business development initiatives and strategic priorities
- Represent the company at industry conferences, meetings, and events, building relationships with key stakeholders in the genomics and biotechnology sectors
- Experience with Next Generation Sequencing (NGS) and/or In Vitro Diagnostics (IVD) is preferred
- Extensive network with key stakeholders in the research, diagnostics and drug development fields a plus
Element Biosciences specializes in next-generation sequencing (NGS) technology, primarily through its product, the AVITI System. This compact benchtop device provides high-quality DNA sequencing at a low cost, charging only $1 per million reads, which is significantly less than the industry average. The AVITI System is designed to deliver industry-leading accuracy, allowing users, including academic researchers and pharmaceutical companies, to maximize their resources. Element Biosciences differentiates itself from competitors by forming partnerships with other biotech firms, such as QIAGEN, to offer complete NGS workflows, enhancing the value of their product. Additionally, the company runs the 2023 AVITI for All Grant program, which provides free sequencing services to support research across various fields. The goal of Element Biosciences is to make high-quality sequencing accessible and affordable, thereby accelerating research and development in the biotechnology sector.
Company Size
201-500
Company Stage
Series D
Total Funding
$678M
Headquarters
San Diego, California
Founded
2017
Simplify's Take
What believers are saying
- AVITI System's low cost per million reads attracts budget-conscious researchers.
- Partnership with Revvity opens new markets in neonatal testing.
- Trinity innovation streamlines genomic research, expanding product offerings.
What critics are saying
- Competition from Illumina and startups pressures Element to innovate and cut costs.
- Frequent AVITI System updates may strain Element's resources.
- Reliance on partnerships poses risks if strategic goals conflict.
What makes Element Biosciences unique
- Element Biosciences offers the AVITI System with dual flow cell layout.
- The company's LoopSeq technology reduces sequencing errors like index hopping.
- AVITI24 introduces the first natively paired spatial multiomic solution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
100% company-paid medical, dental, & vision coverage
Flexible spending & health savings accounts
Premier mental health care
401(k) with immediately vested 4% company match
Company-paid Life and AD&D insurance
Stock option grants
Flexible time off
10 paid annual holidays
8-weeks paid parental leave
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 2%Genome Sequencing Cost CurveFor most of the history of medicine, doctors have been limited to observing symptoms and trying to alleviate them. This has been especially true for non-infectious diseases stemming from dysfunction in the body, including genetic diseases.With the discovery of DNA structure and function, awarded the 1962 Nobel Prize in Medicine , we started to have a better understanding of how the biological system truly works. PCR technology, awarded the 1993 Nobel Prize in Medicine , would open new ways to analyze it.This further expanded when full genomes started to be sequenced. The first human genome was sequenced in 2003 after 13 years of hard work, for a cost of $3B. Quickly, full-genome sequencing started to become cheaper and cheaper. By 2007, it would cost “only” $1M to sequence a full genome
Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the Innovation Roadmap for AVITI24,(TM) the world's first natively paired spatial multiomic solution.
Newsletter Signup - Under Article / In Page"*" indicates required fields Precision medicine is a kind of treatment strategy that is tailored to individual patients, most of which is dependent on their genetic makeup. Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technology, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment. Here are seven genome sequencing startups that are making their mark in the industry.Element BiosciencesFounded in 2017, Element Biosciences shot to fame fairly quickly after the launch of its lab services. Its benchtop sequencing instrument AVITI has a dual flow cell layout and individually addressable lanes and you can perform two parallel runs and operate each side independently. Its alternative model, AVITI LT, is a lower-cost, lower-throughput solution that brings next-generation sequencing (NGS) to more labs.The core components of Element’s sequencing tool include an Avidite base chemistry, which circularizes, copies, and rolls each strand into tightly bound polonies – tiny clusters of identical DNA molecules – without the use of PCR and fluorescent avidites that bind to each polony creating ultrastable complexes. It also employs rolling circle amplification, which is a process that uses a circular DNA template to create long single-stranded DNA molecules to avoid errors such as index hopping – when sequencing reads are incorrectly assigned to the wrong sample in a pool. Its sought-after technology is called LoopSeq, which prepares libraries for long-read sequencing on the short-read Element AVITI System
The collaboration combines Revvity's expertise in newborn screening and rare disease detection with Element's AVITI(TM) sequencing system technology.
Element Biosciences, a U.S. biotech startup, has achieved unicorn status with a valuation over $1 billion and has raised over $680 million. CEO Molly He discussed the company's journey at the Web Summit in Lisbon, highlighting their DNA sequencing device, Aviti, which is used in numerous labs and hospitals. Initial funding included $5 million from Venrock, with subsequent rounds raising $15 million in Series A, $110 million in Series B, and contributions from major investors like Fidelity and RA Capital.